



# DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

**Date:**  
April 20, 2022

**Time:**  
10:00am – 3:00pm (CST)

**Location:**  
MO HealthNet  
[See Additional Meeting Details](#)

### Additional Meeting Details

The April 20<sup>th</sup> DUR meeting will have both in-person and virtual attendance options. The meeting will be hosted at the MO HealthNet Building, 2<sup>nd</sup> Floor, Conference Room 202 located at 615 Howerton Ct, Jefferson City, MO 65109. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**.

Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at [Carmen.M.Burton@dss.mo.gov](mailto:Carmen.M.Burton@dss.mo.gov) or call **(573) 751-6961**.

[Join Webex Meeting](#)

Meeting number (access code): 2456 865 3669  
Meeting password: hR6QCqEej27

**Join from a Video System/Application**  
Dial [24568653669@stateofmo.webex.com](tel:24568653669)  
Or dial 173.243.2.68 and enter the meeting number

**Join from a Mobile Device (attendees only)**  
[1-650-479-3207](tel:16504793207) Call-in toll number (US/Canada)

[\\* Click HERE for Meeting Documents \\*](#)

### Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

### Old Business

10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

### New Business

10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	

### Clinical and Fiscal Edit Review

11:00 – 11:45	<u>Existing Criteria</u>	Josh Moore
	i. Imcivree	
	ii. Megestrol	
	iii. Nulibry	
	iv. Oxervate	
	v. Oxlumo	

- vi. Spravato
- vii. Zokinvy
- viii. Zulresso

New Criteria or Revision of Existing Criteria

- i. Acne or Rosacea, Select Topical Agents
- ii. C5 Complement Inhibitors
- iii. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
- iv. Fabry Disease
- v. Givlaari
- vi. Isturisa
- vii. Scenesse
- viii. Sickle Cell Disease
- ix. Systemic Antifungals
- x. Tavneos
- xi. Voxzogo

**Break**

11:45 – 12:00 Lunch

**Preferred Drug List Edit Review**

12:00 – 2:00 Existing Criteria Josh Moore

- i. Actinic Keratosis Agents, Topical
- ii. Androgenic Agents
- iii. Antibiotics, Inhaled
- iv. Antifungals, Topical
- v. Antihistamines & Antihistamines/Decongestant Combinations, 2<sup>nd</sup> Generation
- vi. Antihistamines, Intranasal
- vii. Antivirals, Herpes Oral
- viii. Antivirals, Topical
- ix. Benzoyl Peroxide/Antibiotic Combinations
- x. Corticosteroids, Oral Inhaled
- xi. Corticosteroids, Topical
- xii. Corticosteroids and Rhinitis Agents, Intranasal
- xiii. Cough/Cold Preparations
- xiv. Epinephrine Agents, Self-Injectable
- xv. Fluoroquinolones, Ophthalmic
- xvi. Fluoroquinolones, Otic
- xvii. Glaucoma Agents
- xviii. Mast Cell Stabilizers, Ophthalmic
- xix. NSAIDs, Ophthalmic
- xx. Psoriasis Agents, Oral
- xxi. Psoriasis Agents, Topical
- xxii. Retinoids, Topical
- xxiii. Ulcerative Colitis Agents, Oral
- xxiv. Ulcerative Colitis Agents, Rectal

New Criteria or Revision of Existing Criteria

- i. Beta Adrenergic Agents, Nebulized
- ii. Beta Adrenergic Agents, Short Acting

- iii. Leukotriene Receptor Modifiers
- iv. Anticholinergics, LABA Combinations
- v. Anticholinergics, LABA/ICS Combinations and PDE4 Inhibitors
- vi. Anticholinergics, Long Acting Inhaled
- vii. Anticholinergics, Short Acting and Combinations Inhaled
- viii. Antifungals, Oral
- ix. Antihistamines, Ophthalmic
- x. Antiparasitics, Topical
- xi. Atopic Dermatitis Agents, Immunomodulators
- xii. Beta Adrenergic Agents, Long Acting
- xiii. Corticosteroids, Ophthalmic Soft
- xiv. Hepatitis C Agents
- xv. Pancreatic Enzymes
- xvi. Respiratory Monoclonal Antibodies

**Program Utilization Information – Conduent Update**

2:00 – 2:30 Reports Jennifer Colozza

- i. Call Center Statistics
- ii. New Drug Statistics
- iii. “Top 25” Drugs by Cost/Claims

**Other Business/Closing Comments**

2:30 – 2:45 Other Business

**Executive Session**

2:45 – 3:00 Patient Profile Reviews

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.*

**Next Meeting: July 20, 2022**  
Meeting location and attendance options subject to change

Missouri Coalition for Community Behavioral Healthcare Lower Level CEO Room 221 Metro Drive, Jefferson City, MO 65109 <i>Public attendance may be limited</i>	Webex
---	-------

***Motion to Close:*** *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*